In May 2003, when India's Patent Act was amended, a new Section 107A was introduced. This provided for a research exemption as an exception to the general rules of patent infringement. Commonly known as a Bolar provision, this research exemption enables a manufacturer of generic drugs to use a patented invention to obtain marketing approval without the patent owner's permission before the patent expires. The generic drug maker can then market their own version of the patented drug as soon as the patent expires.